Company’s Profit After Tax stood at Rs. 538.310 million in Q2FY25.
Praj Industries (Praj), announced its unaudited financial results for the quarter ended Sept 30, 2024.Company’s income from operations stood at Rs. 8,161.920 million in Q2FY25 (Q1 FY25: Rs. 6,991.414 million; Q2 FY24: Rs 8,823.685 million). Company reported Profit Before Tax (PBT) Rs 744.419 million for the period (Q1 FY25: Rs. 788.805 million; Q2 FY24: Rs 848.121 million). Company’s Profit After Tax is at Rs. 538.310 million in Q2FY25 (Q1 FY25: Rs. 841.807 million; Q2 FY24: 623.679 million). Order intake during the quarter Rs. 9,210 million (Q1 FY25: 8,880 million; Q2 FY24: Rs. 10,630 million)
In H1FY25 Company’s Income from operations stood at Rs. 15,153.334 million (H1 FY24: Rs. 16,190.912 million). Company’s PBT before exceptional items is at Rs. 1,533.224 million for the period (H1 FY24: Rs. 1,625.154 million). PBT after exceptional items Rs. 1,814.796 million. In H1FY25 company’s PAT stood at Rs. 1,380.117 million (H1 FY24: Rs. 1,210.405 million). Order intake Rs.18,090 million (H1 FY24: Rs. 21,640 million)
Commenting on the Company’s performance, Shishir Joshipura, CEO & MD, Praj Industries said, “The Bioenergy segment continues to develop positively as we witness our business growing in multiple dimensions, with healthy order and enquiry inflows from international, services and engineering verticals in the first half of the year. Several positive developments in the ecosystem and market augur well for continued growth journey as we move forward. Commissioning of our Demo plant for biopolymers opens a completely new dimension in form of renewable chemicals and materials segment. Our strong focus on R&D backed solutions will continue help us stay on our envisioned growth path”.
Key Developments:
Inauguration of India’s first-of-its-kind Demo Facility for Biopolymers, showcasing indigenously developed integrated Polylactic Acid (PLA) technology at the hands of Union Minister, Dr Jitendra Singh, Ministry of Science & Technology, in the presence of Dr Rajesh Gokhale, Secretary, Dept. of Biotechnology (DBT) and Dr. Ashish Lele (NCL).
